These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8979101)

  • 1. Serum levels of cytokeratin 19 fragments in cervical cancer.
    Nasu K; Etoh Y; Yoshimatsu J; Matsu T; Narahara H; Miyakawa I
    Gynecol Obstet Invest; 1996; 42(4):267-70. PubMed ID: 8979101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
    Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G
    Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
    Tsai SC; Kao CH; Wang SJ
    Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix.
    Ferdeghini M; Gadducci A; Annicchiarico C; Prontera C; Malagnino G; Castellani C; Facchini V; Bianchi R
    Anticancer Res; 1993; 13(5C):1841-4. PubMed ID: 7505543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
    Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
    Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
    Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
    Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
    Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment.
    Pras E; Willemse PH; Canrinus AA; de Bruijn HW; Sluiter WJ; ten Hoor KA; Aalders JG; Szabo BG; de Vries EG
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):23-32. PubMed ID: 11777619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.
    Yamamoto K; Oka M; Hayashi H; Tangoku A; Gondo T; Suzuki T
    Cancer; 1997 May; 79(9):1647-55. PubMed ID: 9128978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
    Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T
    J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
    Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma.
    Sun SS; Hsieh JF; Tsai SC; Ho YJ; Lee JK; Kao CH
    Am J Clin Oncol; 2000 Jun; 23(3):241-3. PubMed ID: 10857885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer.
    Bonfrer JM; Gaarenstroom KN; Kenter GG; Korse CM; Hart AA; Gallee MP; Helmerhorst TJ; Kenemans P
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):371-5. PubMed ID: 7530676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CYFRA 21-1: a new marker of epidermoid cancer of the bronchi. Comparison with 3 other markers].
    Pujol JL; Grenier J; Ray P; Gautier V; Aouta MD; Michel FB
    Presse Med; 1993 Jun; 22(22):1039-42. PubMed ID: 7692432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma].
    Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K
    Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases.
    Piao X; Kong TW; Chang SJ; Paek J; Chun M; Ryu HS
    Gynecol Oncol; 2015 Jul; 138(1):89-93. PubMed ID: 25913134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy.
    Suzuki Y; Nakano T; Ohno T; Abe A; Morita S; Tsujii H
    J Cancer Res Clin Oncol; 2000 Jun; 126(6):332-6. PubMed ID: 10870643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pre-treatment CYFRA 21 - 1 and SCC-Antigen assay in primary cervical carcinoma - a preliminary report.
    Puthucode-Easwaran S; Naik R; Athavale R; Handley G; Lopes A; Godfrey K; Hatem M
    J Obstet Gynaecol; 2005 Jul; 25(5):486-8. PubMed ID: 16183586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High levels of cytokeratin 19 fragments but no evidence of cytokeratins 1, 2, 10/11, 14 or filaggrin in the serum of squamous cell lung carcinoma patients.
    Miédougé M; Devys A; Simon M; Rouzaud P; Salama G; Reyre J; Pujazon M; Carles P; Serre G
    Tumour Biol; 2001; 22(1):19-26. PubMed ID: 11054023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.